広範進展癌症例に対するCOMFP 5剤併用療法のこころみ

概要

論文の詳細を見る
COMFP 5-drug combination therapy using Cyclophosphamide, Vincristin (Oncobin), Methotrexate, 5-FU and Predonine was carried out for patients with advanced head and neck cancer. Of 7 patients treated, 3 patients showed remarkable response, 3 good response and 1 no response. On the other hand, BM (Bleomycin) combination therapy estimated in 8 patients on the same standards yielded remarkable response in none, good response in 3 and no response in 5. COMFP therapy thus proved to be more effective in reducing tumors. In a patient with ten-odd metastatic lesions at the lungs, x-ray examination demonstrated complete disappearance of these lesions after the therapy.The therapeutic effect varied with the different histological types, and remarkable response was more often seen in patients with well-differentiated squamous cell carcinoma.The combination therapy induced severe side-effects in 4 of 7 patients and leukopenia was particularly prominent. The patients recovered in 1 to 2 weeks as long as their general nutritional condition was maintained. Hematological examination once or twice a week was necessary for early detection of side-effects. It was presumed from measurement of peripheral lymphocyte count, PHA skin reaction and PHA-induced lymphocyte transformation that cellular immunity which had already been reduced could deteriorate furthermore.Our experience, although a limited one, and with such a small number of patients, suggests that 3 or 4 courses of administration might be the limit of the therapy in view of side-effects, and that side-effects could develop more slowly and thus be checked more easily with intermittent administration than with continuous administration.The excellent tumor-reducing effect of COMFP combination therapy is attractive, and it seems to be worthy of trial as long as patients are properly selected and evidence of side-effects is carefully supervised.
耳鼻咽喉科臨床学会の論文

広範進展癌症例に対するCOMFP 5剤併用療法のこころみ

スポンサーリンク

概要

著者

関連論文

スポンサーリンク